Fairfield, Bush & Co. Iovance Biotherapeutics, Inc. Transaction History
Fairfield, Bush & Co.
- $168 Billion
- Q3 2024
A detailed history of Fairfield, Bush & Co. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Fairfield, Bush & Co. holds 14,575 shares of IOVA stock, worth $109,166. This represents 0.08% of its overall portfolio holdings.
Number of Shares
14,575
Previous 21,225
31.33%
Holding current value
$109,166
Previous $170 Million
19.6%
% of portfolio
0.08%
Previous 0.1%
Shares
4 transactions
Others Institutions Holding IOVA
# of Institutions
313Shares Held
237MCall Options Held
3.77MPut Options Held
1.7M-
Vanguard Group Inc Valley Forge, PA27.3MShares$205 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY26.6MShares$199 Million6.53% of portfolio
-
Mhr Fund Management LLC New York, NY24MShares$180 Million28.52% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$159 Million0.0% of portfolio
-
State Street Corp Boston, MA13.2MShares$98.9 Million0.01% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $1.18B
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...